Tramazoline

DB13064InvestigationalSmall molecule

Tramazoline is a sympathomimetic indicated for nasal decongestion. Tramazoline is under investigation in clinical trial NCT01601509 (Nasal Tramazoline and Dexamethazone in Obstructive Sleep Apnea (OSA) Patients Tramazoline and).

Formula / weight: C₁₃H₁₇N₃ · 215.3 g/mol (avg)

Resolves to

Compound

UNIISLE31693IVCAS1082-57-1ChEMBLCHEMBL32573ChEBI134893PubChem5524

Clinical / RWD

RxNorm38453ATCR01AA09

Structure

InChIKeyQQJLHRRUATVHED-UHFFFAOYSA-NSMILESC1CN=C(NC2=CC=CC3=C2CCCC3)N1

Targets

P18825ADRA2CP18089ADRA2BP08913ADRA2A

What you can answer from here — as of September 16, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

725Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

11ContraindicationsEach with its own population and attribute set

7Marketed productsAcross 2 countries and 3 labellers

1ATC codeIncluding every combination product, plus 7 drug categories

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tramazoline, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account